Bookmark and Share

Last Minute:          For more news, click here.

Authentication
       
       
Remember me? 

Without price
GENZYME CORPORATI - [Ticker: GENZ]Chart GENZYME CORPORATI  News GENZYME CORPORATI  Download Historical Prices for Metastock GENZYME CORPORATI and Others  Technical Analysis GENZYME CORPORATI  
Last Trade0.00Last Trade Time - 00:00:00
VariationN/A (N/A)Open0.00
High0.00Low0.00
Volume0Average Volume (3m)0
YieldBid / AskN/A
Former Close0.0052 Week Range[0.00 - 0.00]
PER0.00%EPS0.00
Ex-Dividend DateDividend Payment
Market Capitalization0 1 Year Price-Target0.00
Note: The data may have some minutes of delay.
Watch more quotes

Intraday   5 days   1 month   3 months   6 months   1 year   2 years   5 years   10 years            Use this chart on your website!
GENZYME CORPORATI -  [Ticker: GENZ] chart
Change to GENZYME CORPORATI Interactive Technical Analysis Chart

Last 10 Forum Topics about GENZYME CORPORATI:
No topics about GENZYME CORPORATI [GENZ] have been found, but a search on the Forum for more topics related to GENZYME CORPORATI is advised.

 News about GENZYME CORPORATI [GENZ]:   (ordered by relevance)
  1. New Empirical Research Report on Leukemia Therapeutics Market by Forecast to 2021 to 2028 with Covid-19 Impact Analysis  Medgadget
  2. Leukemia Therapeutics Projection By Top Key Players ? Sanofi/ Genzyme Corporation, F. Hoffmann-La Roche, Johnson & Johnson Services, Inc., Amgen Inc., Novartis Market Research Forecast 2028 ? Energy Siren  Energy Siren
  3. Acute Myeloid Leukaemia Therapeutics Market to See constant Growth During, Key Players ? Genzyme Corporation Bristol Myers Squibb Johnson ? Vox Bikol  Vox Bikol
  4. Acute Myeloid Leukemia Therapeutics Market Overview With Detailed Analysis, Competitive Landscape, Forecast to 2027|Ambit Biosciences Corporation, Genzyme Corporation Celgene Corporation, Clavis Pharma ASA ? Clark County Blog  Clark County Blog
  5. Leukemia Therapeutics Market to Hit $27.78 Billion by 2027 Driven By key Players  openPR
Sanofi Unit To Pay $180M In Disease Treatment Patent Fight  Law360 ImmunoGen Appoints Tracey L. McCain, Esq. to Its Board of Directors  Business Wire AGTC Appoints Abraham Scaria, Ph.D., as Chief Science Officer  GlobeNewswire Sigilon Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights  Yahoo Finance Movers & Shakers, July 9 | BioSpace  BioSpace Genzyme Ireland sees 50% growth in profits to ?65.2m  The Irish Times MaxCyte Board Member Richard Douglas, PhD, Appointed  GlobeNewswire Harvard Business School's Baker Library Announces New Collection: John Hawkins Research Interviews about Henri Termeer, Longtime Chairman, CEO, and President of Genzyme Corporation - News  Harvard Business School Gaucher Disease Treatment Market 2021 ? 2028 | Industry In-depth Analysis By Players Genzyme Corporation, Pfizer, Inc., Shire Human Genetics Therapies, Inc.  Medgadget ReForm Biologics Announces Corporate Reorganization  Business Wire The Petri Dish: Former Genzyme CFO joins biologics startup - Boston Business Journal  Boston Business Journal Vericel Expands Executive Leadership Team and Announces Appointment of Patrick Fowler as Senior Vice President, Corporate Development and Strategy  Yahoo Finance FDA Approves New Treatment for Pompe Disease | FDA  FDA.gov Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right  FierceBiotech Graft Versus Host Disease Treatment Market Report 2021-2028 | Size, Share, Growth Factors, Restraining Factors, Revenue, Competitive Landscape, Forecast Analysis  Yahoo Finance Genzyme Completes Sale of Diagnostics Business to Sekisui Chemical Co.  Business Wire Sanofi is betting big on mRNA vaccines after Moderna, Pfizer see success with COVID-19 shots  The Boston Globe Sanofi approaches Genzyme for acquisition: sources  Reuters Sanofi Genzyme's Northborough life science and industrial facility trades for $33 million  Boston Real Estate Times Sanofi-aventis buys Genzyme for $20 billion - Feb. 16, 2011  CNNMoney Sanofi announces settlement agreement related to Contingent Value Rights (CVRs) Litigation  GlobeNewswire Sanofi-Aventis Completes Acquisition of Genzyme Corporation  PR Newswire M&A Objection Lawsuits and Claims for Inadequate Consideration: A ?Bumpy? Road for D&O Insurers  JD Supra Henri A. Termeer Square Officially Dedicated in Cambridge  Business Wire Potential SRT for Neuronopathic Gaucher Shows Efficacy in Early Study  Gaucher Disease News Gemini Therapeutics Announces Appointment of Georges Gemayel, Ph.D. as Chair of Board of Directors  Business Wire Titan Medical Expands Senior Leadership Team  Business Wire Avacta appoints Dr Mark Goldberg as Non-Executive Director  Pharmafield Adagio Therapeutics Appoints Leading Pharmaceutical and Regulatory Executives to its Board of Directors  Business Wire VBI Vaccines Appoints Linda Bain to Board of Directors  Business Wire What Are Some Top Examples of Hostile Takeovers?  Investopedia Exclusive: Relational analysis puts Genzyme value at $93/shr  Reuters AavantiBio Rounds Out Leadership Team with Appointment of Jessie Hanrahan, Ph.D. as Chief Regulatory Officer  Business Wire Sporos Launches with $38.1 Million Series A Financing  GlobeNewswire
For more news about GENZYME CORPORATI click here:
GENZYME CORPORATI News
Search the Internet:

Website Width:
Bookmark and Share

 Background image:

Copyright@2010-2021 - TR4DER.com, all rights reserved.
Investment Forum Stock Quotes Investment News Investment Chat Disclaimer Webmaster Resources